Nanomedicine News

RSS

Kettering to Acquire High-Resolution TEM for Nanoscale Imaging with NSF-MRI Grant

Dr. Ronald J. Tackett, faculty member in the Kettering University department of Physics, along with collaborators from multiple disciplines across campus have been awarded a National Science Foundation - Major Research Instrumentation (NSF-MRI) grant for $452,000. The grant will allow Tackett to acquire a high-resolution transmission electron microscope (TEM) with energy dispersive spectroscopy capabilities to support ongoing investigations and potentially advance materials science and nanotechnology research and teaching at Kettering.

15 Sep 2015

CeloNova Commences Enrolment in Nano-Coated COBRA PzF Coronary Stent System Study

CeloNova BioSciences, Inc. (CN) has announced that it enrolled the first patient in its multicenter e-COBRA clinical study in France. This prospective registry will further assess the safety and efficacy of the novel COBRA PzF coronary stent system in real world and complex patients with heart disease.

15 Sep 2015

NantWorks Enters Agreement with Amgen to Further Develop AMG 337 Cancer Therapeutic

NantPharma, LLC, a subsidiary of NantWorks, LLC, having recently acquired the pharmaceutical product nant-paclitaxel (formerly Cynviloq), today announced that it has entered into an exclusive license agreement with Amgen Inc. for AMG 337. Under the agreement, NantPharma acquired the exclusive rights to develop and commercialize worldwide, excluding Japan, Russia and certain other Central Asian countries, AMG 337, a phase 2 small molecule inhibitor of the cell surface enzyme c-Met, an important target for cancer therapy.

15 Sep 2015

US-Ireland Partnership to Focus on Nanomedicine for Treatment of Pancreatic Cancer

A US-Ireland partnership involving researchers at Queen’s University Belfast has been awarded £2.9m to develop new treatments for pancreatic cancer, which is the fifth most common cause of cancer deaths in the UK.

15 Sep 2015

Scientists Genetically Modify White Blood Cells to Treat Degenerative Neurological Disorders

As a potential treatment for Parkinson's disease, scientists at the University of North Carolina at Chapel Hill have created smarter immune cells that produce and deliver a healing protein to the brain while also teaching neurons to begin making the protein for themselves.

14 Sep 2015

Microfluidics Technology-Based Lab-on-a-Chip Device Could Reduce Cost of Sophisticated Tests for Diseases

Rutgers engineers have developed a breakthrough device that can significantly reduce the cost of sophisticated lab tests for medical disorders and diseases, such as HIV, Lyme disease and syphilis.

14 Sep 2015

Translational Grant for Interaction Study of Laser Radiation with Circulating Tumor Cells and Melanin Nanoparticles

University of Arkansas for Medical Sciences (UAMS) researcher Vladimir Zharov, Ph.D., D.Sc., was awarded a $1.7 million grant by the National Cancer Institute for clinical testing of a new technology called Theranostics, which is an integration of early diagnosis and treatment of melanoma.

14 Sep 2015

Full Data Set from Novavax RSV F Vaccine Clinical Trial Published in Journal of Infectious Disease

Novavax, Inc., a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the full data set from its clinical trial of the RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in women of childbearing age (18-35 years) were published in the Journal of Infectious Disease. The Company previously announced top-line results from the trial.

From Novavax Inc. 14 Sep 2015

Celsion Provides Update on Development of GEN-1 for Ovarian and Brain Cancer

Celsion Corporation, a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies for the treatment of cancer and other difficult-to-treat diseases, announced today that the Company has completed the integration of its June 2014 acquisition of EGEN, Inc. and has provided an update on its clinical development plans for GEN-1, the Company's DNA-based immunotherapy for the localized treatment of ovarian and brain cancer.

10 Sep 2015

Dosing Commences in BIND Therapeutics’ BIND-014 iNSITE 2 Trial in Patients with Four Tumor Histologies

BIND Therapeutics, Inc., a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, today announced that patient dosing is underway in the iNSITE 2 trial, a global, phase 2, two-stage clinical trial of BIND-014 in patients with four tumor histologies.

10 Sep 2015

Nanomedicine News

Kettering to Acquire High-Resolution TEM for Nanoscale Imaging with NSF-MRI Grant

CeloNova Commences Enrolment in Nano-Coated COBRA PzF Coronary Stent System Study

NantWorks Enters Agreement with Amgen to Further Develop AMG 337 Cancer Therapeutic

US-Ireland Partnership to Focus on Nanomedicine for Treatment of Pancreatic Cancer

Scientists Genetically Modify White Blood Cells to Treat Degenerative Neurological Disorders

Microfluidics Technology-Based Lab-on-a-Chip Device Could Reduce Cost of Sophisticated Tests for Diseases

Translational Grant for Interaction Study of Laser Radiation with Circulating Tumor Cells and Melanin Nanoparticles

Full Data Set from Novavax RSV F Vaccine Clinical Trial Published in Journal of Infectious Disease

Celsion Provides Update on Development of GEN-1 for Ovarian and Brain Cancer

Dosing Commences in BIND Therapeutics’ BIND-014 iNSITE 2 Trial in Patients with Four Tumor Histologies

Combining Nanofluids and Turbulators for Sustainable Energy

Enhancing Material Properties through Nanotube Encapsulation

Brain-Inspired Nano-Tech Promises New Era for Electronics

Breakthrough in 2D Material Growth Opens Doors to Cleaner Energy and Next-Generation Technology

Nanopore-Based Sensor Enables Rapid and Precise Disease Diagnosis

Electrospinning and the Future of Nanotechnology

How Electrospinning is Shaping the Future of Nanotechnology

Conversations on AFM: Applications of BioAFM in Life Science

Sponsored Content

Characterization of Active Pharmaceutical Ingredients, Injectables, and Proteins

The Future of Wound Care: Why Nanofibers are Key to Accelerated Healing

The Evolution of Lipid Nanoparticles

How Emulsion Electrospinning is Transforming Materials